SCHEDULE: Janus Henderson Reports 3% Stake in Ocugen

Janus Henderson Group Ltd. has disclosed a beneficial ownership of 3.0% in Ocugen, Inc., holding 10,000,000 shares and warrants.

Summary

• Janus Henderson Group Ltd. (JHG) has filed an amendment to its Schedule 13G, reporting beneficial ownership of Ocugen, Inc. common stock.
• The filing indicates that JHG, through its various asset management subsidiaries, beneficially owns 10,000,000 shares and warrants, representing 3.0% of the class of securities.
• This filing is an amendment, with the event date requiring the filing being June 30, 2026.
• JHG clarifies that while its asset managers exercise investment and/or voting discretion, they do not have the right to receive dividends or proceeds from the sale of these securities and disclaim ownership associated with such rights.
• No single asset manager owns more than five percent of Ocugen, Inc.'s common stock.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership percentage and not containing operational or financial performance updates.

Positives

• Disclosure of a significant institutional investor's stake can signal confidence in the company's long-term prospects.
• The filing clearly delineates the ownership structure and clarifies the role of asset managers versus the ultimate parent company.

Negatives

• The filing does not provide any new operational or financial performance data for Ocugen, Inc.
• The disclosure is a routine filing for beneficial ownership and does not indicate new investment strategy or conviction beyond the reported stake.

Risks

• The filing does not explicitly mention any risks related to Ocugen, Inc.'s business operations or financial health.
• Potential for future changes in Janus Henderson's stake, which could impact Ocugen's stock price, is an inherent market risk.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Ocugen, Inc.'s future performance. It solely reports on beneficial ownership.

Management Comments

• In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Janus Henderson Group Ltd. It does not include securities, if any, beneficially owned by Janus Henderson Group Ltd.s ultimate parent Jupiter Topco LLC, the direct or indirect owners of Jupiter Topco LLC, or other persons that may be deemed under control of such owners. Any beneficial ownership by such persons has been disaggregated from that of Janus Henderson Group Ltd. in accordance with the release.
• The Asset Managers generally exercise investment and/or voting discretion on behalf of their clients which include investment companies, other investment advisers, institutional separate accounts and retail separate accounts (collectively referred to herein as Managed Portfolios).
• However, the Asset Managers do not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaim any ownership associated with such rights.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. Janus Henderson's disclosure of a 3.0% stake in Ocugen places them as a notable institutional shareholder, a common occurrence in the biotechnology sector where significant capital is often required for development and commercialization.

Comparison to Industry Standards

• The filing does not provide specific performance metrics for Ocugen, Inc. to compare against industry standards.
• The 3.0% ownership stake by Janus Henderson is a common threshold for institutional investors to report beneficial ownership under SEC regulations, aligning with standard practices for investment firms managing large portfolios.

Stakeholder Impact

• Shareholders: The disclosure may be viewed positively as it indicates institutional interest, potentially increasing demand for shares. However, it does not provide new information about Ocugen's performance.
• Management of Ocugen, Inc.: The filing confirms a significant institutional investor's presence, which could lead to increased engagement or scrutiny.
• Creditors: No direct impact is indicated as the filing is about equity ownership, not debt.

Next Steps

• Janus Henderson Group Ltd. will continue to monitor its beneficial ownership of Ocugen, Inc. securities.
• Further amendments to Schedule 13G will be filed if ownership levels change significantly or as required by regulations.

Key Dates

Keywords

beneficial ownership, Schedule 13G, institutional investor, asset management, common stock, warrants, shareholder